PepGen Announces IND-Enabling Preclinical Data Supporting Progression of PGN-EDODM1 into Clinical Studies | PepGen
![Applied StemCell Inc on X: "ASC can develop preclinical assays to determine efficacy, pharmacodynamic, dose-ranging studies, biodistribution, and develop other IND-enabling assays to measure potency and toxicity of the drug including NHPs, Applied StemCell Inc on X: "ASC can develop preclinical assays to determine efficacy, pharmacodynamic, dose-ranging studies, biodistribution, and develop other IND-enabling assays to measure potency and toxicity of the drug including NHPs,](https://pbs.twimg.com/media/E8C2rZoUcAEdt4d.jpg)
Applied StemCell Inc on X: "ASC can develop preclinical assays to determine efficacy, pharmacodynamic, dose-ranging studies, biodistribution, and develop other IND-enabling assays to measure potency and toxicity of the drug including NHPs,
![Verve Therapeutics on X: "Today we are excited to announce anticipated 2022 milestones including timing of first HeFH patient treated with VERVE-101 & initiation of IND-enabling studies for our ANGPTL3 program. Read Verve Therapeutics on X: "Today we are excited to announce anticipated 2022 milestones including timing of first HeFH patient treated with VERVE-101 & initiation of IND-enabling studies for our ANGPTL3 program. Read](https://pbs.twimg.com/media/FIvaH41WYAIeLyt.png:large)